Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Eledon Pharmaceuticals (NASDAQ: ELDN or the Company), is a small cap, development-stage biotech company whose lead candidate, tegoprubart, inhibits CD40 ligand (CD40L, or CD154) binding of T-cells with CD40 receptors on B-cells and dendritic cells, which serves to reduce the T-cell mediated immuneAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ELDN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am no ...